US Urges Denial of Gilead Bid to Alter HIV Drug-Patents Judgment

The federal government urged a judge to reject Gilead Sciences Inc.’s request to alter a May 2023 judgment that two drugs in its HIV-prevention regimen directly infringe voided government-owned patents, calling the effort “untimely” and “improper.”

Gilead’s April 17 motion suggested the judgment could be misinterpreted as holding the company liable for direct infringement. The government’s opposition, filed Wednesday in the US District Court for the District of Delaware, said such “speculation regarding a potential misinterpretation does not constitute the clear error of law or demonstrate the need to prevent manifest injustice that is required to grant” Gilead’s request ...